You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Xellia Pharms Aps Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for XELLIA PHARMS APS, and when can generic versions of XELLIA PHARMS APS drugs launch?

XELLIA PHARMS APS has fourteen approved drugs.

There are eight US patents protecting XELLIA PHARMS APS drugs.

There are fifty patent family members on XELLIA PHARMS APS drugs in thirty countries and twenty-six supplementary protection certificates in nine countries.

Summary for Xellia Pharms Aps
International Patents:50
US Patents:8
Tradenames:9
Ingredients:9
NDAs:14

Drugs and US Patents for Xellia Pharms Aps

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Exclusivity Expiration
Xellia Pharms Aps MICAFUNGIN SODIUM micafungin sodium INJECTABLE;INTRAVENOUS 211713-001 Jun 2, 2021 AP RX No No ⤷  Subscribe ⤷  Subscribe
Xellia Pharms Aps VANCOMYCIN HYDROCHLORIDE vancomycin hydrochloride SOLUTION;INTRAVENOUS 211962-003 Feb 15, 2019 RX Yes Yes 11,628,200 ⤷  Subscribe Y ⤷  Subscribe
Xellia Pharms Aps VANCOMYCIN HYDROCHLORIDE vancomycin hydrochloride SOLUTION;INTRAVENOUS 211962-004 Feb 15, 2019 RX Yes Yes 10,188,697 ⤷  Subscribe Y ⤷  Subscribe
Xellia Pharms Aps VANCOMYCIN HYDROCHLORIDE vancomycin hydrochloride SOLUTION;INTRAVENOUS 211962-001 Feb 15, 2019 RX Yes Yes 10,849,956 ⤷  Subscribe Y ⤷  Subscribe
Xellia Pharms Aps VANCOMYCIN HYDROCHLORIDE vancomycin hydrochloride SOLUTION;INTRAVENOUS 211962-002 Feb 15, 2019 RX Yes Yes 11,628,200 ⤷  Subscribe Y ⤷  Subscribe
Xellia Pharms Aps VANCOMYCIN HYDROCHLORIDE vancomycin hydrochloride SOLUTION;INTRAVENOUS 211962-002 Feb 15, 2019 RX Yes Yes 11,517,609 ⤷  Subscribe ⤷  Subscribe
Xellia Pharms Aps VANCOMYCIN HYDROCHLORIDE vancomycin hydrochloride SOLUTION;INTRAVENOUS 211962-001 Feb 15, 2019 RX Yes Yes 11,517,609 ⤷  Subscribe ⤷  Subscribe
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Exclusivity Expiration
Showing 1 to 7 of 7 entries

International Patents for Xellia Pharms Aps Drugs

CountryPatent NumberEstimated Expiration
Brazil 112020003862 ⤷  Subscribe
Canada 3070660 ⤷  Subscribe
China 111093625 ⤷  Subscribe
Costa Rica 20170234 ⤷  Subscribe
Japan 6797795 ⤷  Subscribe
Philippines 12017500720 ⤷  Subscribe
Singapore 11201703568W ⤷  Subscribe
>Country>Patent Number>Estimated Expiration
Showing 1 to 7 of 7 entries

Supplementary Protection Certificates for Xellia Pharms Aps Drugs

Patent NumberSupplementary Protection CertificateSPC CountrySPC ExpirationSPC Description
1280520 122015000021 Germany ⤷  Subscribe PRODUCT NAME: TOBRAMYCIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/10/652/001-003 20110720
1115417 22/2006 Austria ⤷  Subscribe PRODUCT NAME: DAPTOMYCIN; REGISTRATION NO/DATE: EU/1/05/328/001 UND 002 20060119
1280520 92678 Luxembourg ⤷  Subscribe PRODUCT NAME: TOBRAMYCINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE. FIRST REGISTRATION: 20110725
1115417 CA 2006 00018 Denmark ⤷  Subscribe PRODUCT NAME: DAPTOMYCIN
0620232 SPC/GB02/002 United Kingdom ⤷  Subscribe A SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB02/002 GRANTED TO MERCK SHARP + DOHME, CORP IN RESPECT OF THE PRODUCT CASPOFUNGIN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY CASPOFUNGIN ACETATE, WHICH WAS ADVERTISED AS COMING INTO FORCE IN JOURNAL NO 5919 DATED 30 OCTOBER 2002 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, IT WILL EXPIRE ON 24 OCTOBER 2016.
1115417 SPC/GB06/024 United Kingdom ⤷  Subscribe SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB06/024 GRANTED TO CUBIST PHARMACEUTICALS, INC IN RESPECT OF THE PRODUCT DAPTOMYCIN, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6162 DATED 27 JUNE 2007 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 22 JANUARY 2021.
0788511 SPC/GB08/036 United Kingdom ⤷  Subscribe PRODUCT NAME: MICAFUNGIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN PARTICULAR MICAFUNGIN SODIUM; REGISTERED: UK EU/1/08/448/001 20080425; UK EU/1/08/448/002 20080425
>Patent Number>Supplementary Protection Certificate>SPC Country>SPC Expiration>SPC Description
Showing 1 to 7 of 7 entries
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.